{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:30:33Z","timestamp":1786973433790,"version":"build-2736575974"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Malignant pleural mesothelioma (MPM) exhibits substantial molecular and cell-state heterogeneity, together with marked spatial variation in its immune and stromal microenvironment. Histological classification and individual biomarkers alone cannot adequately explain its evolution or heterogeneous treatment responses. This review critically integrates genomic, epigenomic, transcriptomic, single-cell, and spatial omics evidence along a conceptual continuum encompassing tumor-intrinsic molecular evolution, microenvironmental ecosystem remodeling, candidate stratification, and precision therapy. Current evidence indicates that alterations involving\n                    <jats:italic>BAP1, CDKN2A\/MTAP<\/jats:italic>\n                    , and the\n                    <jats:italic>NF2<\/jats:italic>\n                    \/Hippo pathway impose evolutionary constraints and create candidate therapeutic vulnerabilities but are insufficient to determine functional phenotypes independently. Epithelioid, uncommitted, and sarcomatoid malignant cell states may coexist within the same genetic clone, while immune and stromal features display pronounced regional heterogeneity. Based on published human MPM cohorts, we further propose four provisional immune-ecosystem archetypes: T-cell\u2013inflamed, B-cell\/tertiary lymphoid structure\u2013organized, myeloid-dominant, and immune-desert. Tumor-intrinsic molecular states and stromal\u2013spatial features are treated as interpretive modifiers. This literature-derived framework is intended for hypothesis generation and has not been developed or validated as a clinical classifier. At present, the principal value of multi-omics lies in mechanistic discovery and the design of biomarker-enriched clinical trials. Future studies should employ standardized assays in multicenter cohorts, independent external validation, formal archetype-by-treatment interaction testing within randomized trials, and longitudinal sampling to determine the treatment-predictive value and clinical feasibility of this framework.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1883870","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:25:30Z","timestamp":1786623930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongmei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunzhong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Wang","sequence":"additional","affiliation":[{"name":"Puer Central Hospital, Simao District People\u2019s Hospital","place":["Puer, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiteng","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurav","family":"Poudel","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The People\u2019s Hospital of Chu Xiong Yi Autonomous Prefecture","place":["Chu Xiong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca-cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2013.0319","article-title":"Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health","volume":"110","author":"Neumann","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15022","article-title":"Chinese expert consensus on the diagnosis and treatment of Malignant pleural mesothelioma","volume":"14","author":"Wang","year":"2023","journal-title":"Thorac Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with Malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.22985","article-title":"Quantitative relationships of exposure to chrysotile asbestos and mesothelioma mortality","volume":"62","author":"Loomis","year":"2019","journal-title":"Am J Ind Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12778","article-title":"Global trends in mortality from Malignant mesothelioma: Analysis of WHO mortality database (1994-2013)","volume":"12","author":"Abdel-Rahman","year":"2018","journal-title":"Clin Respir J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2017.04.09","article-title":"Epidemiology and trend analysis on Malignant mesothelioma in China","volume":"29","author":"Zhao","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00895-7","article-title":"Pleural mesothelioma classification-update and challenges","volume":"35","author":"Dacic","year":"2022","journal-title":"Modern Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneumo.2018.06.004","article-title":"Clinical and pathological profile of the pleural Malignant mesothelioma: A retrospective study about 30 cases","volume":"74","author":"Mlika","year":"2018","journal-title":"Rev Pneumol Clin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cells11182924","article-title":"Define the two molecular subtypes of epithelioid Malignant pleural mesothelioma","volume":"11","author":"Saddozai","year":"2022","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable Malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-05-4642","article-title":"Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey","volume":"66","author":"Dogan","year":"2006","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2024.118878","article-title":"The influence of cation exchange on the possible mechanism of erionite toxicity: A synchrotron-based micro-X-ray fluorescence study on THP-1-derived macrophages exposed to erionite-Na","volume":"252","author":"Raneri","year":"2024","journal-title":"Environ Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.49.9616","article-title":"Clinicopathologic characteristics of Malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma","volume":"31","author":"Chirieac","year":"2013","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12989-016-0162-4","article-title":"The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases","volume":"13","author":"Sayan","year":"2016","journal-title":"Part Fibre Toxicol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.305","article-title":"TNF-receptors on human peritoneal mesothelial cells: regulation of receptor levels and shedding by IL-1 alpha and TNF alpha","volume":"50","author":"Douvdevani","year":"1996","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/ki.1994.359","article-title":"Human peritoneal mesothelial cells synthesize IL-1 alpha and beta","volume":"46","author":"Douvdevani","year":"1994","journal-title":"Kidney Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.12.8194","article-title":"Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells","volume":"181","author":"Eigenbrod","year":"2008","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"P Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41416-019-0661-9","article-title":"Metabolic rewiring and redox alterations in Malignant pleural mesothelioma","volume":"122","author":"Urso","year":"2020","journal-title":"Brit J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cells12162048","article-title":"Chronic inflammation, oxidative stress and metabolic plasticity: Three players driving the pro-tumorigenic microenvironment in Malignant mesothelioma","volume":"12","author":"Fiorilla","year":"2023","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in Malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-23-0423","article-title":"Low exposures to amphibole or serpentine asbestos in germline Bap1-mutant mice induce mesothelioma characterized by an immunosuppressive tumor microenvironment","volume":"4","author":"Kadariya","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-04-2219","article-title":"SV40 enhances the risk of Malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study","volume":"65","author":"Cristaudo","year":"2005","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1080\/08958370600835377","article-title":"The role of SV40 in Malignant mesothelioma and other human Malignancies","volume":"18","author":"Pershouse","year":"2006","journal-title":"Inhal Toxicol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-05-0127","article-title":"SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure","volume":"65","author":"Cacciotti","year":"2005","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.170207097","article-title":"Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity","volume":"97","author":"Bocchetta","year":"2000","journal-title":"P Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205203","article-title":"SV40 infection induces telomerase activity in human mesothelial cells","volume":"21","author":"Foddis","year":"2002","journal-title":"Oncogene"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1213238109","article-title":"High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by Malignant pleural mesothelioma","volume":"109","author":"Mazzoni","year":"2012","journal-title":"P Natl Acad Sci USA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.10040","article-title":"Evidence against a role for simian virus 40 in Malignant mesothelioma in Japan","volume":"24","author":"Hiraki","year":"2006","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/gtmb.2023.0532","article-title":"Association study of pleural mesothelioma and oncogenic simian virus 40 in the crocidolite-contaminated area of dayao county, yunnan province, southwest China","volume":"44","author":"Liu","year":"2023","journal-title":"Genet Test Mol Biomarkers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13073-022-01060-8","article-title":"Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in Malignant pleural mesothelioma","volume":"14","author":"Creaney","year":"2022","journal-title":"Genome Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Brit J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100706","article-title":"Correlation of histologic features with gene alterations in pleural mesothelioma","volume":"38","author":"Fanaroff","year":"2025","journal-title":"Modern Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100915","article-title":"Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma","volume":"4","author":"Pandey","year":"2023","journal-title":"Cell Rep Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02577-3","article-title":"BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms","volume":"42","author":"Singh","year":"2023","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13073-021-00931-w","article-title":"Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in Malignant pleural mesothelioma","volume":"13","author":"Meiller","year":"2021","journal-title":"Genome Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7619\/jcmp.20212725","article-title":"Study on the role of arginine methyltransferase 5 in methionine phosphorylase-deficient Malignant pleural mesothelioma","volume":"25","author":"Zhang","year":"2021","journal-title":"Clin Med J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15213","article-title":"PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach","volume":"24","author":"Barbarino","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41698-024-00627-5","article-title":"NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity","volume":"8","author":"Xu","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41420-022-01232-w","article-title":"SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated Malignant mesothelioma","volume":"8","author":"Suzuki","year":"2022","journal-title":"Cell Death Discov"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of Malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0804","article-title":"Integrative molecular characterization of Malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of Malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat Genet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"124928","DOI":"10.2139\/ssrn.4548436","article-title":"Integrated DNA methylation analysis of peripheral blood from asbestos exposed populations and patients with Malignant mesothelioma reveals novel methylation driver genes of diagnostic and prognostic relevance","volume":"362","author":"Feng","year":"2024","journal-title":"Environ pollut"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.015","article-title":"DNA methylation as a diagnostic biomarker for Malignant mesothelioma: a systematic review and meta-analysis","volume":"16","author":"Vandenhoeck","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-3683","article-title":"Somatic epigenetic silencing of RIPK3 inactivates necroptosis and contributes to chemoresistance in Malignant mesothelioma","volume":"27","author":"Tan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jtho.2020.08.024","article-title":"UHRF1 is a novel druggable epigenetic target in Malignant pleural mesothelioma","volume":"16","author":"Reardon","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-3040","article-title":"Epigenetic silencing of microRNA-34b\/c plays an important role in the pathogenesis of Malignant pleural mesothelioma","volume":"17","author":"Kubo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2021.4950","article-title":"Overexpression of microRNA-486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting PIM1","volume":"47","author":"Pinelli","year":"2021","journal-title":"Int J Mol Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41419-020-02940-w","article-title":"P53-regulated miR-320a targets PDL1 and is downregulated in Malignant mesothelioma","volume":"11","author":"Costa","year":"2020","journal-title":"Cell Death Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01441-7","article-title":"Essential role of the histone lysine demethylase KDM4A in the biology of Malignant pleural mesothelioma (MPM)","volume":"125","author":"Lapidot","year":"2021","journal-title":"Brit J Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02330-x","article-title":"SETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53","volume":"129","author":"Xu","year":"2023","journal-title":"Brit J Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated Malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in Malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01950-z","article-title":"A combination of intrinsic and extrinsic features improves prognostic prediction in Malignant pleural mesothelioma","volume":"127","author":"Nguyen","year":"2022","journal-title":"Brit J Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1038\/s41467-021-25173-7","article-title":"The pathogenesis of mesothelioma is driven by a dysregulated translatome","volume":"12","author":"Grosso","year":"2021","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216950","article-title":"Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC translation in Malignant pleural mesothelioma","volume":"592","author":"Gugnoni","year":"2024","journal-title":"Cancer Lett"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-23-0017","article-title":"Single-cell view of tumor microenvironment gradients in pleural mesothelioma","volume":"14","author":"Giotti","year":"2024","journal-title":"Cancer Discov"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-025-01639-9","article-title":"Fibroblast-like cells in mesothelioma can derive from tumor cells","volume":"33","author":"Garcia-Manteiga","year":"2026","journal-title":"Cell Death Differ"},{"key":"B65","doi-asserted-by":"publisher","first-page":"103529","DOI":"10.1016\/j.jtho.2025.11.019","article-title":"Multiomic, histologic, and scRNA-seq profiling of pleural mesothelioma reveals negative prognosis associated with a novel uncommitted molecular phenotype","volume":"21","author":"Severson","year":"2026","journal-title":"J Thorac Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-023-01816-9","article-title":"Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic Malignant pleural mesothelioma: new paradigms for immunotherapy","volume":"22","author":"Torricelli","year":"2023","journal-title":"Mol Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210836120","article-title":"Defining and targeting tumor-associated macrophages in Malignant mesothelioma","volume":"120","author":"Wu","year":"2023","journal-title":"P Natl Acad Sci USA"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1159\/000538520","article-title":"Characterization of pleural mesothelioma by hierarchical clustering analyses using immune cells within tumor microenvironment","volume":"91","author":"Inaguma","year":"2024","journal-title":"Pathobiology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-026-03421-1","article-title":"Multiplexed single-cell and spatial profiling reveal B cells and tertiary lymphoid structures as prognostic indicators in pleural mesothelioma","volume":"135","author":"Rigutto","year":"2026","journal-title":"Brit J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15326","article-title":"Genomic and T cell repertoire biomarkers associated with Malignant mesothelioma survival","volume":"15","author":"Nie","year":"2024","journal-title":"Thorac Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13046-025-03522-4","article-title":"CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma","volume":"44","author":"Torricelli","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.03.518966","article-title":"Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma","volume":"63","author":"Obacz","year":"2024","journal-title":"Eur Respir J"},{"key":"B73","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13046-022-02582-0","article-title":"Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met\/PI3K and WNT signaling but do not protect against cisplatin","volume":"42","author":"Ries","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cells12152006","article-title":"Primary and hTERT-transduced mesothelioma-associated fibroblasts but not primary or hTERT-transduced mesothelial cells stimulate growth of human mesothelioma cells","volume":"12","author":"Ries","year":"2023","journal-title":"Cells"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1268927","article-title":"Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with Malignant pleural mesothelioma","volume":"14","author":"Qualiotto","year":"2023","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-23-0524","article-title":"Spatial landscape of Malignant pleural and peritoneal mesothelioma tumor immune microenvironments","volume":"4","author":"Ma","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-1767","article-title":"Evolution of genomic and T-cell repertoire heterogeneity of Malignant pleural mesothelioma under dasatinib treatment","volume":"26","author":"Chen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215116","article-title":"The immunological landscape of M1 and M2 macrophages and their spatial distribution in patients with Malignant pleural mesothelioma","volume":"15","author":"Laberiano-Fernandez","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/cells13242135","article-title":"Myeloid cell mobilization and recruitment by human mesothelioma in NSG-SGM3 mice","volume":"13","author":"Shindyapin","year":"2024","journal-title":"Cells"},{"key":"B80","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12967-025-06193-z","article-title":"The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes","volume":"23","author":"Torricelli","year":"2025","journal-title":"J Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-6194","article-title":"Abstract 6194: Spatial architecture of immunochemotherapy response in pleural mesothelioma","volume":"86","author":"Chun","year":"2026","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"A504","DOI":"10.1136\/jitc-2020-sitc2020.0473","article-title":"473\u2005Mavrilimumab, a human monoclonal antibody targeting GM-CSFR\u03b1, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro","volume":"8","author":"Carvajal","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-3757","article-title":"Tumor-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients","volume":"24","author":"Khanna","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2026.117361","article-title":"Cooperative response loops enhanced by histamine signaling during tumor-neutrophil crosstalk in pleural mesothelioma","volume":"45","author":"Sueyoshi","year":"2026","journal-title":"Cell Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-4024","article-title":"Ad-SGE-DKK3 gene therapy overcomes resistance to immune checkpoint blockade in pleural mesothelioma","volume":"31","author":"Jang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s12967-025-06407-4","article-title":"Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB","volume":"23","author":"Belgiovine","year":"2025","journal-title":"J Transl Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae973","article-title":"Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.09.1968","article-title":"Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of Malignant pleural mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100672","article-title":"BAP1 deficiency inflames the tumor immune microenvironment and is a candidate biomarker for immunotherapy response in Malignant pleural mesothelioma","volume":"5","author":"Xu","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007585","article-title":"PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma","volume":"11","author":"Homicsko","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105786","article-title":"Epithelioid pleural mesothelioma is characterized by tertiary lymphoid structures in long survivors: results from the MATCH study","volume":"23","author":"Mannarino","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/0471463752.tnmc22","article-title":"Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages","volume":"11","author":"Ch\u00e9n\u00e9","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"JNCI-J Natl Cancer I"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"JNCI-J Natl Cancer I"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41467-024-55316-5","article-title":"MAT2A inhibitor AG-270\/S095033 in patients with advanced Malignancies: a phase I trial","volume":"16","author":"Gounder","year":"2025","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04029-3","article-title":"YAP\/TEAD inhibitor VT3989 in solid tumors: a phase 1\/2 trial","volume":"31","author":"Yap","year":"2025","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13046-025-03283-0","article-title":"miRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma","volume":"44","author":"Piccioni","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-20-0637","article-title":"Silencing of SmgGDS, a novel mTORC1 inducer that binds to RHEBs, inhibits Malignant mesothelioma cell proliferation","volume":"19","author":"Sato","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1186\/s12885-023-11636-1","article-title":"LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in Malignant pleural mesothelioma: a retrospective study","volume":"23","author":"Arimura","year":"2023","journal-title":"BMC Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030673","article-title":"Recent advances of immune checkpoint inhibition and potential for (combined) TIGIT blockade as a new strategy for Malignant pleural mesothelioma","volume":"10","author":"Rovers","year":"2022","journal-title":"Biomedicines"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123199","article-title":"Manganese-coordinated nanoparticles loaded with CHK1 inhibitor dually activate cGAS-STING pathway and enhance efficacy of immune checkpoint therapy","volume":"319","author":"Huang","year":"2025","journal-title":"Biomaterials"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-22-0017","article-title":"Activation of tumor-cell STING primes NK-cell therapy","volume":"10","author":"Knelson","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117636","article-title":"Preparation and anti-tumor applications of universal umbilical cord blood-derived, mesothelin-targeted CAR-T cells","volume":"245","author":"Gao","year":"2026","journal-title":"Biochem Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with Malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2024.2377830","article-title":"Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment","volume":"13","author":"Chatelain","year":"2024","journal-title":"Oncoimmunology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/0008-5472.CAN-24-3822","article-title":"Pharmacogenomic characterization of a large cohort of patient-derived cell lines identifies therapeutic strategies for pleural mesothelioma","volume":"86","author":"Assi\u00e9","year":"2026","journal-title":"Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znad178.002","article-title":"Hyperthermic intrathoracic chemotherapy (HITOC) improves Malignant pleural mesothelioma control through a tumor specific cytotoxic immune response","volume":"110","author":"Cavin","year":"2023","journal-title":"Br J Surg"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-24-0245","article-title":"Hyperthermic intrathoracic chemotherapy modulates the immune microenvironment of pleural mesothelioma and improves the impact of dual immune checkpoint inhibition","volume":"13","author":"Hao","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-7147","article-title":"Abstract 7147: Ultra-high throughput single-nuclei RNAs sequencing of Malignant pleural mesothelioma samples in the BEAT-MESO clinical trial","volume":"85","author":"Buszta","year":"2025","journal-title":"Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20188746","article-title":"Current best practices in single-cell RNA-seq analysis: a tutorial","volume":"15","author":"Luecken","year":"2019","journal-title":"Mol Syst Biol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02048-6","article-title":"Systematic assessment of tissue dissociation and storage biases in single-cell and single-nucleus RNA-seq workflows","volume":"21","author":"Denisenko","year":"2020","journal-title":"Genome Biol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-022-01409-2","article-title":"Museum of spatial transcriptomics","volume":"19","author":"Moses","year":"2022","journal-title":"Nat Methods"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2018.07.028","article-title":"Tumor-specific genetic variants can be detected in circulating cell-free DNA of Malignant pleural mesothelioma patients","volume":"124","author":"Hylebos","year":"2018","journal-title":"Lung Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1883870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:19:24Z","timestamp":1786972764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1883870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":117,"alternative-id":["10.3389\/fonc.2026.1883870"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1883870","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1883870"}}